Hemostasis disorders and their correction using disaggregates and low-molecular heparins in patients with idiopathic fibrosing alveolitis (IFA) Source: Eur Respir J 2004; 24: Suppl. 48, 320s Year: 2004
Hemocoagulation and platelet aggregation disorders in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2002; 20: Suppl. 38, 226s Year: 2002
The study of C5a complement component in patients with idiopathic pulmonary fibrosis, toxic fibrosing alveolitis and extrinsic allergic alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 108s Year: 2001
Plasma fibronectin as the criterion of idiopathic fibrosing alveolitis severity Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017
Hemostasis disorders and their correction using ticlopidine in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2003; 22: Suppl. 45, 84s Year: 2003
Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001
Idiopathic fibrosing alveolitis (IFA) as a background for the lung cancer development Source: Eur Respir J 2002; 20: Suppl. 38, 479s Year: 2002
CT features of fibrosing alveolitis in rheumatoid arthritis (FARA): a comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003
Fibrosing alveolitis in rheumatoid arthritis (FARA):a survival comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF) Source: Eur Respir J, 51 (4) 1702519; 10.1183/13993003.02519-2017 Year: 2018
Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: 43S-55S Year: 2001
15-year follow-up of patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002
Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF) Source: Eur Respir J 2007; 30: Suppl. 51, 121s Year: 2007
Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Specific features of the course of cryptogenic fibrosing alveolitis in pregnancy Source: Eur Respir J 2001; 18: Suppl. 33, 150s Year: 2001
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009
Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002
Lung cancer in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008